Andreas Fouras

Spoke with Grady Wulff at Bell Potter on what’s driving 4DMedical: extracting more from standard lung scans no workflow change. Now in leading US hospitals. CT:VQ™ is the only FDA-approved, injection-free lung blood flow scan gaining traction. Watch: youtube.com/watch?v=srG8o7…

Today we released our half-year report, a defining period for 4DMedical, showcasing execution, validation and growing global momentum. None of this is possible without the dedication of our incredible team. Half year report: announcements.asx.com.au/asxpdf/2026022…

Australia is entering a once-in-a-generation moment for life sciences where solving real clinical problems isn’t just good science, it’s becoming one of the most powerful investment signals in the market. @4DMedicalXV

_ @4DMedicalXV's commercial momentum is accelerating. UMiami has commenced clinical use of CT:VQ™, becoming the second U.S. academic medical centre after Stanford. We also confirm a two-year agreement with Lahey Hospital & Medical Center | cdn-api.markitdigital.com/apiman-gateway…

Coming to you live from the @RSNA conference, I've just held an investor webinar outlining the significant progress @4DMedicalXV is making. Commercial traction across major segments and RSNA confirms the shift happening now. I’m excited about where we are and where we’re going.

This week at RSNA, @4DMedicalXV showcased the FDA-cleared CT:VQ™ the world’s first non-contrast perfusion imaging technology. CT:VQ™ delivers ventilation + perfusion from a standard chest CT with no contrast, no inhaled agents and no added scan time. rsna.org

4DMedical will be at RSNA this month, showcasing CT:VQ™ to the global radiology community. We’ll be meeting clinicians, partners and decision-makers, demonstrating how we help detect lung disease earlier and more precisely. Learn more: rsna.org @4DMedicalXV

This week in Sydney, we shared how 4DMedical is enabling earlier detection and treatment of lung disease improving outcomes for patients & clinicians. Thanks to those who joined us, including John Hester (Bell Potter) & our CCO, Matt Tucker. 4dmedical.com/investor/compa… @4DMedicalXV

FY25 AGM reflected a year of strong execution & growing momentum for @4DMedicalXV CT:VQ™ now FDA cleared, reimbursed & in use at Stanford Medicine, alongside expanding Lung Health Screening programs. Chair Letter: announcements.asx.com.au/asxpdf/2025103… Q1 FY26 Report: announcements.asx.com.au/asxpdf/2025103…

_ @4DMedicalXV attended CHEST 2025 in Chicago, where our CT:VQ™ tech the world’s first to show lung perfusion without injection received a strong reception from US pulmonologists. Exciting momentum as we expand across the US! Learn more about CHEST here: chestphysician.org/annual-meeting

Exciting momentum for @4DMedical @StanfordMed becomes the first U.S. AMC to adopt CT:VQ™ commercially, just weeks after FDA clearance. At the same time, our partnership with @AstraZeneca expands in Brazil to 5 new hospitals - 38,000 CT scans annually. announcements.asx.com.au/asxpdf/2025102…

Proud to see 4DMedical featured in the AFR among top Aussie techs with global potential. “The next Pro Medicus,” says The Super Investor’s Paul Nojin. We’re transforming respiratory diagnostics worldwide. (AFR, sub req) afr.com/markets/equity… @4DMedicalXV @FinancialReview

September was a milestone month for 4DMedical (ASX:4DX) – $22.6m raised via options, $10m from Pro Medicus & $6m R&D rebate, taking pro forma cash to $45.5m. Strong backing fuels CT:VQ™ rollout, US expansion & RSNA 2025 prep. ASX: cdn-api.markitdigital.com/apiman-gateway… @4DMedicalXV

4DMedical will hold its Annual General Meeting on Thursday, 30 Oct 2025 at 12pm AEDT at our Melbourne HQ. We look forward to updating shareholders on progress and our vision ahead. Notice of AGM: cdn-api.markitdigital.com/apiman-gateway… Annual report: cdn-api.markitdigital.com/apiman-gateway… @4DMedicalXV

4DMedical has released its Annual Report. FY25 was a year of meaningful progress across every part of our business. Annual report: announcements.asx.com.au/asxpdf/2025092… @4DMedicalXV

I was interviewed by Alan Kohler in Intelligent Investor on 4DMedical’s FDA clearance and what’s next for our technology. Read here (free account sign-up required): intelligentinvestor.com.au/investment-new… @AlanKohler @4DMedicalXV

Following a transformational period for 4DMedical (ASX:4DX) I was pleased to discuss the implications of these historic milestones for us on The Stock Network. Lel Smits invited to share my perspective. To watch the full interview please click here: youtu.be/nkulCFon5t8

The 4DMedical team was excited to showcase CT:VQ™ at the PERT Consortium’s 11th Annual Meeting in San Diego. Clinicians across the PE care pathway showed strong interest we look forward to advancing these conversations. pertconsortium.org/pert-annual-sy… @4DMedicalXV

I’m pleased to invite our shareholders to join a special 4DMedical webinar featuring a fireside chat between Dr Kyle Hogarthand Tom Godfrey. Date: Wed, 17 Sep 2025 Time: 12pm – 12:45pm AEST Register here: teams.microsoft.com/dl/launcher/la…  announcements.asx.com.au/asxpdf/2025091…

A great example of successful university commercialisation from @monashengineers led by the entrepreneurial @AFouras. More to come like this from @MonashUni. @AlanTudgeMP